To determine the efficacy of oral supplementation of the gut enzyme intestinal alkaline phosphatase (IAP) in preventing antibiotic-associated infections from Salmonella enterica serovar Typhimurium (S. Typhimurium) and Clostridium difficile. Background: The intestinal microbiota plays a pivotal role in human health and well-being. Antibiotics inherently cause dysbiosis, an imbalance in the number and composition of intestinal commensal bacteria, which leads to susceptibility to opportunistic bacterial infections. Previously, we have shown that IAP preserves the normal homeostasis of intestinal microbiota and that oral supplementation with calf IAP (cIAP) rapidly restores the normal gut flora. We hypothesized that oral IAP supplementation would protect against antibiotic-associated bacterial infections. Methods: C57BL/6 mice were treated with antibiotic(s) ± cIAP in the drinking water, followed by oral gavage of S. Typhimurium or C. difficile. Mice were observed for clinical conditions and mortality. After a defined period of time, mice were killed and investigated for hematological, inflammatory, and histological changes. Results: We observed that oral supplementation with cIAP during antibiotic treatment protects mice from infections with S. Typhimurium as well as with C. difficile. Animals given IAP maintained their weight, had reduced clinical severity and gut inflammation, and showed improved survival. Conclusions: Oral IAP supplementation protected mice from antibioticassociated bacterial infections. We postulate that oral IAP supplementation could represent a novel therapy to protect against antibiotic-associated diarrhea (AAD), C. difficile-associated disease (CDAD), and other enteric infections in humans.
opportunistic enteric pathogenic infections is an unfortunate consequence of this treatment. 1 It is believed that the destruction of the normal commensal flora by antibiotics allows pathogenic bacteria to more easily infect the host. For example, streptomycin-treated mice can be infected with a very small number of Salmonella enterica serovar Typhimurium (S. Typhimurium) (<10 colony-forming units, CFU), whereas approximately 1 million CFU are required to infect untreated control animals. In 1971, Waaij et al 2 demonstrated that antibiotic treatment made mice more susceptible to colonization by Escherichia coli, Klebsiella pneumonia, and Pseudomonas aeruginosa. Recent work by Sekirov et al 3 demonstrated that antibiotic-mediated alterations of the intestinal microbiota in mice were dose-dependent, and the greater was the perturbation, the greater was the susceptibility to S. Typhimurium. Chen et al 4 developed a mouse model for Clostridium difficile-associated disease (CDAD) and found that oral gavage of 10 5 CFU of C. difficile precipitated severe CDAD in antibiotic-treated mice, resulting in death within 3 days. On the contrary, the same CFU of C. difficile failed to cause disease in mice not exposed to an antibiotic. These observations of increased susceptibility to pathogens in animals exposed to antibiotics are also relevant to humans. Recently, Glynn et al 5 conducted a population-based, case-control study using data from the Food-borne Diseases Activity Surveillance Network (FoodNet) during 1996-1997 and found that prior antibiotic treatment (during the 4 weeks preceding illness onset) increases the risk of sporadic infections with multidrug-resistant S. Typhimurium.
Extensive epidemiological studies have shown that antibioticassociated diarrhea (AAD), an unwanted consequence of an antimicrobial therapy, is due to changes in the composition and function of the commensal intestinal flora, with the consequential overgrowth of opportunistic pathogenic bacteria, especially Clostridium difficile. [6] [7] [8] We have recently shown that the brush-border enzyme intestinal alkaline phosphatase (IAP) preserves the normal homeostasis of intestinal microbiota. 9 Furthermore, oral administration of calf IAP (cIAP) along with an antibiotic rapidly restores the gut flora that would otherwise be lost due to the antibiotic treatment, indicating a prebiotic (compound that promotes commensal bacterial growth) role for IAP. Further, we showed that oral IAP supplementation dramatically reduced colonization with S. Typhimurium in mice. Based on these observations, we developed the hypothesis that the maintenance and/or rapid restoration of normal gut flora in the setting of antibiotic administration would prevent pathogenic bacterial infection by competing for "food and shelter (mucosal attachment sites)." In this article, we provide evidence that co-administration of IAP during an antibiotic therapy protects mice from the enteric pathogens S. Typhimurium and C. difficile.
Animals
Mice (Mus musculus C57BL/6) were bred at the Massachusetts General Hospital (MGH) Animal Facility (Boston, MA). Eight-weekold female mice were housed in a biosafety level 2 (BL2) room in hard top cages, with 5 animals per cage. Mice were maintained in a temperature-controlled room (22-24 • C) with a 12-hour light/12-hour dark diurnal cycle with food and water ad libitum. The Institutional Animal Care and Use Committee (IACUC) at MGH reviewed and approved all the animal experiments.
Bacterial Culture
Clostridium difficile strain VPI 10463 (ATCC 43255) stock suspension was grown in Difco cooked meat media and incubated anaerobically for 48 hours at 37 • . Streptomycin-resistant Salmonella enterica serovar Typhimurium SL1344 (NCTC 13347) was grown in BHI media and Hektoen plates containing streptomycin (100 μg/mL) in ambient air at 37 • overnight.
Salmonella Infection
Groups of mice (n = 5) received streptomycin (5 mg/mL) in their drinking water. Simultaneous with streptomycin, 1 group received cIAP (200 U/mL) in the drinking water (cIAP + group), whereas the other group (cIAP − group) received the "vehicle for cIAP" [50 mM of KCl, 10 mM of Tris-HCl (pH 8.2), 1 mM of MgCl 2 , 0.1 mM of ZnCl 2 , 50% glycerol] in the drinking water. Antibiotic (streptomycin) treatment continued for 3 days, and 2 days after discontinuation of antibiotic, mice received approximately 5000 CFU of S. Typhimurium by oral gavage. cIAP/vehicle treatment continued for further 5 days (total 10 days) when the experiment was terminated.
Induction of C. difficile Colitis
Similar to the strategy for infecting mice with S. Typhimurium (see above), groups of mice (n = 5) received streptomycin ± cIAP in their drinking water. This combination was given for 3 days, then on day 4, streptomycin was discontinued but IAP/vehicle was continued. Also, on day 4, animals from both groups received intraperitoneal injections of clindamycin (10 mg/kg body weight). On day 6, IAP/vehicle was discontinued and both groups received approximately 1000 CFU of C. difficile by oral gavage. The protocol for antibiotics and C. difficile dosage was determined through repeated experiments, and this final protocol was repeated twice with reproducible results. In addition, IAP activity was monitored in the stool to verify similar intake of the enzyme in the animals that received it.
Clinical Score
To assess the clinical condition, the rating scale developed by Lankowski and Hohmann 10 was followed (also see Supplemental Digital Content Data File, available at: http://links.lww.com/SLA/ A380). Clinical scoring was performed by a single-blind researcher.
Interleukin-1 Beta Assay
The ELISA kit from eBioscience was used to quantitate interleukin-1 beta (IL-1β) levels in blood samples and colonic segments.
Intestinal Alkaline Phosphatase Assay
IAP activity was determined by hydrolyzing p-nitrophenyl phosphate (pNPP) as previously described 9, 11 (also see Supplemental Digital Content Data File, available at: http://links.lww.com/SLA/ A380).
C. difficile Toxin Assay
Stool samples were collected on ice and the toxin assay was done using the Premier Toxins A & B kit from Meridian Bioscience (Cincinnati, OH).
Mouse Colon Histology
Hematoxylin and eosin (H&E) slides were made from different sections of the colon and graded by a single-blind pathologist following the protocol as previously described 12 (also see Supplemental Digital Content Data File, available at: http://links.lww.com/SLA/A380).
Myeloperoxidase Assay
The myeloperoxidase (MPO) assay was performed using odianisidine dihydrochloride method as previously described [13] [14] [15] (also see Supplemental Digital Content Data File (available at: http://links. lww.com/SLA/A380).
Colon Organ Culture
One centimeter of the colonic segment was collected and cultured following the protocol as previously described 16 (also see Supplemental Digital Content Data File, available at: http://links.lww. com/SLA/A380).
RESULTS

Oral Supplementation With IAP Reduces Intestinal Colonization and Systemic Translocation of S. Typhimurium
Mice (C57BL/6) were treated with streptomycin ± cIAP, followed by oral gavage with S. Typhimurium. The animals were then killed 5 days after S. Typhimurium infection and tissues were examined for colonization and translocation. We observed that the colonic luminal content of the control cIAP − mice had approximately 25-fold more S. Typhimurium compared with the cIAP + animals (4.5E+09 ± 1.9E+09 vs. 1.9E+08 ± 8.5E+07 CFU/g, respectively). Similarly, the cecal content of the cIAP − group also had approximately 20fold higher S. Typhimurium count compared with the cIAP + group (1.7E+10 ± 2.7E+09 vs. 9.0E+08 ± 3.0E+08 CFU/g, respectively) ( Fig. 1A) .
To determine whether IAP also affects mucosal colonization, we measured the number of S. Typhimurium attached to the mucosa. The colonic mucosa of the cIAP − group had approximately 10-fold more S. Typhimurium compared with the cIAP + group (4.2E+05 ± 1.3E+05 vs. 4.4E+04 ± 5.1E+03 CFU/g, respectively). Similarly, cecal mucosa of the cIAP − group contained nearly 4-fold more S. Typhimurium count compared with the cIAP + group (4.9E+05 ± 1.4E+05 vs. 1.2E+05 ± 9.3E+03 CFU/g, respectively) ( Fig. 1B) . Figure 1C shows the data on systemic translocation of S. Typhimurium from the gut to the mesenteric lymph nodes (MLN), liver, and spleen. The MLN of the cIAP − group had about 3-fold more S. Typhimurium compared with that of the cIAP + group (1.8E+05 ± 1.4E+05 vs. 5.7E+04 ± 3.2E+04 CFU/g tissue, respectively). The liver of the cIAP − animals had about 7-fold more S. Typhimurium compared with the liver of the cIAP + animals (2.5E+05 ± 2.4E+05 vs. 3.7E+04 ± 6.7E+03 CFU/g tissue, respectively). Although a higher number of S. Typhimurium translocated to the spleen in the cIAP − mice compared with the cIAP + mice, the difference was not statistically significant (4.7E+05 ± 3.2E+05 vs. 4.0E+05 ± 2.5E+05 CFU/g tissue, respectively). In a separate set of experiments with a different antibiotic, mice were treated with amoxicillin ± cIAP followed by S. Typhimurium gavage and we found a higher number of S. Typhimurium translocated to the MLN, liver, and spleen in the FIGURE 1. Oral supplementation with cIAP reduces intestinal colonization and systemic translocation of Salmonella Typhimurium. Groups of mice (n = 5) were co-treated with streptomycin (5 mg/mL) ± cIAP (200 U/mL) in the drinking water for 3 days. Two days after discontinuation of streptomycin, mice were gavaged with 5000 colony-forming units (CFU) of S. Typhimurium. cIAP treatment continued for another 5 days (total 10 days). Mice were killed 5 days after bacterial gavage and CFU in different tissues were determined. Values are expressed as mean ± SEM. * P < 0.05 (Student t test). A, S. Typhimurium CFU in the luminal content of the colon and cecum. B, S. Typhimurium CFU in the mucosa of the colon and cecum. C, S. Typhimurium CFU in the mesenteric lymph nodes (MLN), liver, and spleen.
cIAP − mice compared with the cIAP + mice, all of the differences being statistically significant (data not shown).
Oral Supplementation With IAP Improves the Clinical Condition of S. Typhimurium-Infected Mice
We recorded the daily individual weights of S. Typhimuriuminfected mice, and a line graph showing the percentage change in the weights of each group of animals is presented in Figure 2A . The animals in the cIAP + group experienced normal weight gain, whereas those in the cIAP − group suffered significant weight loss. In addition, we assessed the clinical conditions of the mice daily, following a blinded protocol, and calculated the clinical scores based on the Lankowski and Hohmann scale. 10 As shown in Figure 2B , from day 3 onward, the differences in clinical score between the 2 groups were statistically significant.
To determine the local inflammatory status in the gut, we measured the MPO activity in different segments of the intestine. The MPO activity in most intestinal segments was similar between the groups, except in the cecal tissue, where the MPO activity was significantly higher in the cIAP − mice (3.92 ± 0.35 vs. 2.88 ± 0.17 units/g cecal tissue, respectively; see Fig. 2C ). Finally, we also analyzed a variety of hematological parameters and found no statistically significant difference in the WBC, differential, and platelet counts, but did observe lower hemoglobin levels in the cIAP − mice compared with the cIAP + mice (9.87 ± 1.63 vs 12.40 ± 0.47 g/dL of blood, respectively; see Table 1 ).
IAP Supplementation Rapidly Restores the Gut Flora Lost Due to a Multiple Antibiotic Regimen
We next explored the effects of oral IAP supplementation on CDAD. We modified an established model of CDAD 4 by using only 2 antibiotics, streptomycin (5 mg/mL drinking water) and clindamycin (10 mg/kg body weight, intraperitoneal injection). Before oral gavage with C. difficile, we determined the effects of IAP on the restoration of the gut flora after discontinuation of the 2 antibiotics. Consistent with our previous report, 9 IAP was able to rapidly restore the gut flora, as determined by plating of stool samples aerobically on MacConkey (Fig. 3A) and BHI agar plates (Fig. 3B ). The MacConkey agar plate selects for the Gram-negative bacteria Enterobacteriaceae, eg, E. coli. In the case of cIAP + mice, we observed the growth of approximately 2.17E+06 ± 1.26E+06 CFU/g stool on the MacConkey agar plates on day 6, and most of these CFU were E. coli colonies. Interestingly, the stools of the cIAP − mice contained no Gram-negative bacteria on day 6. The BHI plate allows the growth of most types of bacteria, and as expected, we observed that the stool of both groups produced CFU on these plates; however, the stools of the cIAP + mice contained approximately 10-fold more bacteria compared with the stools of the cIAP − mice (6.27E+06 ± 3.32E+06 vs. 6.43E+05 ± 2.97E+05 CFU/g stool, respectively). Although these data are statistically significant, it is important to note that the majority of the intestinal flora is anaerobic, and aerobes, as determined here, comprise a very small portion of total bacteria and thus can only be considered a surrogate marker of total bacterial composition and number. To verify that the mice took in similar amounts of IAP, we assayed the stool IAP activity levels in the treatment group and found that it was similar between the animals within that group (data not shown). In addition, we measured daily water consumption during the antibiotic treatment period to ensure similar intake by the different groups and no significant differences were found (data not shown). Oral IAP supplementation improves clinical conditions in mice infected with S. Typhimurium (for the description of animals see Figure 1 and also "Methods"). Mice were observed for weight and clinical conditions for 5 days after bacterial gavage. For determining myeloperoxidase (MPO) activity, the cecal tissue was homogenized by sonication and the supernatant was collected after centrifugation followed by an MPO assay. MPO activity was expressed as average units/gm cecal tissue ± SD. A, Percentage change in weight of mice infected with S. Typhimurium and treated with cIAP (cIAP + ) or without cIAP (cIAP − ). * P < 0.05 (Student t test). B, Clinical score of mice infected with S. Typhimurium and treated with cIAP (cIAP + ) or without cIAP (cIAP − ). * * * P < 0.001 (Student t test). C, MPO activity in the cecal tissue of mice infected with S. Typhimurium and treated with cIAP (cIAP + ) or without cIAP (cIAP − ).
* P < 0.05, * * * P < 0.001 (Student t test). Oral supplementation with cIAP rapidly restores the normal gut flora in mice after discontinuation of treatment with multiple antibiotics. Groups of mice were co-treated with antibiotics (streptomycin 3 days orally, followed by a single intraperitoneal injection of clindamycin on day 4) ± cIAP (200 U/mL). Individual stool samples were grown on MacConkey agar plates (A) and brain heart infusion (BHI) agar plates (B). Please note that on days 2 to 5, animals from both groups did not grow any bacterial colonies from the collected stool samples, indicating the effectiveness of the antibiotic treatment. Values are expressed as average CFU/gm stool ± SEM. * P < 0.05, * * * P < 0.001 (Student t test). 
IAP Supplementation Improves the Clinical Condition of C. difficile-Infected Mice
After antibiotic treatment, we exposed the mice to approximately 1000 CFU of C. difficile via oral gavage. We monitored the weights of each animal daily and observed that though the cIAP + mice mostly maintained their original weight, the cIAP − mice had significant loss of weight within a few days (approximately 15% on day 4) ( Fig. 4A ). We also observed the clinical conditions of the mice following a blinded protocol and calculated clinical scores as described above. Figure 4B shows that there was no significant difference between the 2 groups for the first 2 days; however, from day 3, the animals in the control group started getting sick, whereas all the animals in the cIAP + group stayed healthy. This difference was even more marked on day 4.
We then measured the levels of C. difficile toxins (A and B) in the stools of individual animals. Figure 4C shows the clearance rate of toxins from the 2 groups of mice. It is evident that the cIAP + mice rapidly cleared their toxins (by day 5, all the mice were free of toxins), whereas all of the cIAP − mice still had toxins in their stool. In a separate set of experiments using 8 IAP-treated mice compared with 9 controls, IAP supplementation led to an improvement in survival, most evident on day 6, when almost 80% of the cIAP − mice died compared with only 25% of the cIAP + mice.
IAP Supplementation Minimizes Intestinal Mucosal Injury in C. difficile-Infected Mice
We evaluated the status of intestinal injury in both groups of mice by histological analyses (H&E staining) of different colonic segments (histological analyses were carried out by a pathologist who was blinded to the groups). Inflammatory scoring was assigned based on an established protocol. 12 Figure 5A shows that all the colonic segments of the cIAP − group had more inflammatory injury compared with the respective colonic segments of the cIAP + group. The proximal colonic segments had the most injury and the degree of inflammation decreased in the more distal regions. The differences in the histological scores among the respective colonic segments of the 2 groups were statistically significant. Figures 5B and 5C show representative sections of the distal colon from the cIAP − and cIAP + mice, respectively, demonstrating more extensive colonic mucosal injury in the cIAP − mice (see epithelial disruption (e)).
IAP Supplementation Prevents Inflammatory Changes
We performed organ culture of the colonic segments of the animals and measured IL-1β levels in the culture media. We found that IL-1β levels were approximately 10-fold higher in the cIAP − mice compared with cIAP + mice (1229.71 ± 99.34 vs. 138.15 ± 24.61 pg/mL culture media, respectively) and this difference was statistically significant (Fig. 6 ). We also analyzed the hematological parameters of the cIAP − and cIAP + mice and found that that there was no statistically significant difference in the counts of WBC, neutrophils, or platelets (Table 1 ). However, similar to the case of S. Typhimurium infection, we observed lower hemoglobin levels in the cIAP − mice compared with the cIAP + mice (13.70 ± 0.66 vs. 14.83 ± 0.56 g/dL blood, respectively) and the difference was statistically significant (Table 1 ).
DISCUSSION
The intestinal microbiota plays a pivotal role in maintaining human health and well-being. 9, [17] [18] [19] [20] Dysbiosis, defined as an imbalance in the number and composition of intestinal microbes, is considered to be the cause or consequence of various diseases, including AAD, 21, 22 CDAD, 23 salmonellosis, 1,3 AIDS, 24 diabetes, 25 and obesity. 26 Antibiotics cause dysbiosis by definition, because their purpose is the killing of bacteria; however, the type and extent of such dysbiosis obviously depends on the microbial targets of the specific antibiotic, suggesting the probable existence of antibiotic-specific dysbiotic profiles of Oral supplementation with cIAP minimizes colonic injury in C. difficile-infected mice (for the description of animals, see Figure 3 and also "Methods"). Groups of mice were co-treated with antibiotics (streptomycin 3 days orally, followed by a single intraperitoneal injection of clindamycin on day 4) ± cIAP (200 U/mL). On day 6, IAP/vehicle was discontinued and both groups received approximately 1000 CFU of C. difficile by oral gavage. Mice were killed 4 days after C. difficile infection. Hematoxylin and eosin (H&E) staining was performed on slides from different segments of the colon and the mucosa was examined. Lesions were graded based on an established grading system. 12 A, Histological score of mice infected with C. difficile and treated with cIAP (cIAP + ) or without cIAP (cIAP − ). The lower the score, the better the outcome. Oral supplementation with cIAP minimizes inflammation. Mice were treated with cIAP (cIAP + ) or without cIAP (cIAP − ) for 5 days and then infected with C. difficile (for the description of animals, see Figure 3 and also "Methods"). Animals were killed 4 days after C. difficile infection. Colonic segments were obtained and organ culture was performed. Using an ELISA kit, proinflammatory cytokine IL-1β levels were determined in the colon organ culture media. Values are expressed as pg/mL culture media ± SD. * * * P < 0.001 (Student t test).
intestinal microbiota. At present, little is known about the specific dysbiotic profile that occurs with a given antibiotic treatment.
In this study, we assessed the efficacy of IAP in the prevention of the short-term consequences of antibiotic-induced dysbiosis, specifically salmonellosis and CDAD. IAP is a brush-border enzyme that is exclusively produced by the enterocytes of the proximal small intestine, and the enzyme is secreted into the intestinal lumen. 27 Physiologically, IAP exerts many functions, including detoxifying bacterial toxins, 28 dephosphorylating ATP, 29 limiting fat absorption, 30 regulating host-microbial interaction and gut mucosal defense, 31,32 maintaining local gut immunity, 33 and preserving intestinal microbiotal homeostasis. 9 The pharmacological properties of exogenous IAP include prevention of sepsis, 34 peritonitis, 15 and bacterial pathogenesis. 9 IAP has also been used to treat inflammatory bowel disease in animal models as well as in humans. 14, 35 Because IAP is a naturally occurring gut enzyme, it can be safely administered orally and does not appear to be associated with any side effects.
On the basis of the described prebiotic and anti-inflammatory properties of IAP, we predicted that IAP would not only prevent bacterial pathogenesis, but also ameliorate inflammatory symptoms due to infection. Indeed, in the present study, we demonstrated the efficacy of oral IAP supplementation in preventing antibiotic-induced susceptibility of mice to S. Typhimurium and C. difficile infections, 2 major global health problems. S. enterica is a Gram-negative bacterium that causes typhoid fever and gastroenteritis. 36 S. enterica serovar Typhi (S. Typhi) is mostly responsible for typhoid fever, whereas nontyphoidal Salmonella (NTS) strains cause food poisoning, called salmonellosis. It was estimated that in 2000, the global burden of typhoid cases was 21.7 million, out of which 217,000 patients died. 37 NTS salmonellosis affects approximately 3 billion people worldwide and causes 200,000 deaths every year. 38 In the United States, approximately 1.4 million Salmonella infections occur and 600 people die annually. 5 The estimated costs of medical care and loss of productivity due to Salmonella infection ranges from 0.5 to 2.3 billion dollars/year in the United States. 5 CDAD is already a major health problem in developed countries, and is more recently emerging in developing countries. [6] [7] [8] 39 C. difficile infection alone is responsible for approximately 3 million cases of diarrhea and pseudomembranous colitis annually in the United States, and the mortality rate varies from 1 to 2.5%. 23, 40 Infection rates for C. difficile are reported to be approximately 10% after 2 weeks of hospitalization, but may reach 50% after 4 or more weeks. 40 In addition, the incidence of C. difficile infection is 20 to 100 times higher in patients greater than 60 years of age than in patients 10 to 20 years of age. 21 Hospitalized patients with C. difficile infections have a death rate of 4% to 10%. 40 A conservative estimate of the annual US cost for CDAD management is 3.2 billion dollars. 41 We believe that the beneficial effects of IAP seen in this study are likely related to the ability of this enzyme to rapidly restore the commensal gut microflora in the context of antibiotic treatment. Previously work from our laboratory did not show any direct effect of IAP on multiple bacterial species (including Salmonella) when grown together in vitro. 9 In addition, it is also important to note that in the C. difficile experiments, IAP administration was stopped prior to the administration of C. difficile such that IAP did not directly interact with the bacteria and/or its toxins. As such, we believe that protection by IAP against antibiotic-induced infections is due to its ability to rapidly restore the normal commensal gut flora, rather than a direct inhibitory effect on the bacteria themselves. It is likely that the normal commensal flora creates a healthier environment within the gut that is less favorable to pathogenic bacterial growth.
The beneficial impact of the IAP supplementation was seen in regard to the relative resistance to infection by the 2 pathogens, Salmonella and C. difficile. The decreased inflammation within the colon, as evidenced by histology and blunted IL-1β response in organ culture, reflects the lesser degree of colitis, resulting in higher hemoglobin levels due to less blood loss in the stool.
CONCLUSIONS
In conclusion, we believe that oral supplementation with IAP during antibiotic treatment may represent a novel way to prevent bacterial infections due to Salmonella, C. difficile, and perhaps other enteric pathogens in humans.
